Long-Term GLP-1 Treatment: Genetics, Nutrition, Muscle Preservation and Weight Maintenance

Last updated: November 2026 | Evidence review

GLP-1 medications have transformed the management of obesity and metabolic disease. Medicines such as semaglutide and tirzepatide can produce substantial weight loss, improve several cardiometabolic risk factors and, in appropriate patients, provide benefits that extend beyond the number on the weighing scale.

However, achieving weight loss is only part of the treatment journey. Other important questions emerge as treatment progresses:

  • Why do some people lose substantially more weight than others taking the same medication?
  • Can genetics help explain differences in medication response and side effects?
  • How can nutritional deficiencies and muscle loss be prevented?
  • Should patients continue treatment indefinitely after reaching their target weight?
  • Can a lower maintenance dose preserve weight-loss benefits?
  • What happens when someone reduces, stops or changes their medication?

These questions should not be considered separately. They form part of a broader approach to personalized, long-term obesity management.

This guide brings together emerging pharmacogenomic research, nutritional evidence, body-composition studies and clinical trials investigating the maintenance and discontinuation of GLP-1-based therapies.

Key takeaways
  • Obesity often requires long-term management rather than a short course of medication.
  • Genetic differences contribute to variations in weight-loss response and adverse effects, but genetic testing is not yet a routine prescribing tool.
  • Reduced food intake can increase the risk of inadequate protein and micronutrient intake.
  • Resistance training and adequate dietary protein are important for preserving muscle during weight reduction.
  • Stopping GLP-1 treatment commonly leads to weight regain, although individual outcomes vary.
  • New 2026 evidence supports individualised maintenance dosing, including the potential value of reducing tirzepatide to 5 mg in suitable patients.

1. The Long-Term GLP-1 Treatment Challenge

GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists work through hormonal pathways involved in glucose regulation, appetite and food intake.

Semaglutide activates the GLP-1 receptor, while tirzepatide activates both the GIP and GLP-1 receptors.

By influencing appetite regulation, satiety, gastric emptying and glucose-dependent insulin secretion, these medications can help people achieve substantial reductions in body weight.

However, the physiological processes contributing to obesity do not necessarily disappear after weight loss.

Appetite-regulating hormones, energy expenditure and other biological mechanisms can change during weight reduction. Consequently, maintaining weight loss after discontinuing medication can be difficult.

This is why obesity is increasingly approached as a chronic disease requiring ongoing management.

2. Why Do Some People Respond Better to GLP-1 Medications?

One of the most important unanswered questions in obesity pharmacotherapy is why two people receiving the same medication at similar doses can experience substantially different outcomes.

Some patients achieve substantial weight loss, while others experience a smaller response, plateau earlier or discontinue treatment because of adverse effects.

Possible contributing factors include:

  • Genetic differences affecting drug targets and biological pathways.
  • Age, sex, baseline body composition and metabolic health.
  • Presence of type 2 diabetes and other metabolic conditions.
  • Medication type, dose, treatment duration and adherence.
  • Dietary intake, physical activity, sleep and behavioural factors.
  • Gastrointestinal tolerability and individual differences in drug response.

Genetics is emerging as an additional piece of this complex puzzle.

2.1 The 2026 Nature study: Genetic predictors of GLP-1 response

A major pharmacogenomic study published in Nature on April 8, 2026, investigated genetic differences associated with weight-loss efficacy and adverse effects among people using GLP-1 medications.

The researchers from the 23andMe Research Institute conducted a genome-wide association study involving 27,885 people who had reported using semaglutide, tirzepatide or related preparations.

The study identified important associations involving two genes: GLP1R and GIPR.

Finding 1: GLP1R and weight-loss response

GLP1R encodes the receptor targeted by GLP-1 receptor agonist medications.

Researchers identified a genetic variant, rs10305420, associated with greater weight-loss response.

Each copy of the effect allele was associated with approximately:

  • 0.641 percentage points greater BMI reduction.
  • Approximately 0.76 kg additional weight loss.

Although the individual effect was modest, the finding provides biological evidence that genetic variation in the drug's target pathway contributes to differences in treatment response.

Finding 2: GIPR and gastrointestinal side effects

The researchers also identified an association involving GIPR, the gene encoding the glucose-dependent insulinotropic polypeptide receptor.

The genetic association was particularly relevant to nausea and vomiting among people taking tirzepatide, which acts on both GIP and GLP-1 receptors.

One particularly interesting finding involved people carrying risk-associated variants at both the GLP1R and GIPR loci.

Individuals homozygous for the relevant risk alleles had approximately 14.8-fold higher odds of tirzepatide-associated vomiting than individuals homozygous for the non-risk alleles.

This is an association in a particular genetic subgroup. It should not be interpreted as a 14.8-fold absolute probability of vomiting or as an established clinical prediction rule.

Finding 3: Genetics is only part of the picture

The researchers developed prediction models combining genetic information with demographic, clinical and treatment characteristics.

The combined model explained approximately 25% of the variation in weight-loss response, with most of the predictive contribution coming from non-genetic factors.

The findings are encouraging, but substantial unexplained variation remains.

What are the limitations?

Several considerations are important:

  • The study relied substantially on self-reported treatment and weight-loss information.
  • Approximately 82% of participants were female.
  • Approximately 78% were of European ancestry.
  • The genetic associations do not establish that testing will improve treatment outcomes.
  • The prediction models require additional validation before they can be routinely applied to prescribing decisions.

Clinical implication: Genetic testing for GLP-1 response is not currently a routine requirement before prescribing semaglutide or tirzepatide. Nevertheless, this study provides an important foundation for future precision obesity medicine.

It also reinforces an important message: a limited response to a GLP-1 medication does not necessarily reflect a lack of effort or motivation.

Reference: Su QJ et al. Genetic predictors of GLP1 receptor agonist weight loss and side effects. Nature. 2026;653:770–775. DOI: 10.1038/s41586-026-10330-z.

3. Nutritional Deficiencies During GLP-1 Treatment

One of the less visible challenges of GLP-1 treatment is maintaining adequate nutrition while eating substantially less food.

Although appetite suppression is central to the effectiveness of these medications, consuming fewer calories can also mean consuming less protein, fibre, vitamins and minerals.

Nausea, vomiting, constipation, food aversions and early satiety can further restrict dietary variety and nutritional adequacy.

3.1 The 2025 study involving 461,382 patients

A retrospective observational study by Butsch and colleagues, published in Obesity Pillars in 2025, investigated nutritional deficiencies and related complications among adults newly prescribed GLP-1 receptor agonists.

The researchers analysed insurance claims data involving 461,382 adults prescribed GLP-1 receptor agonists between July 2017 and December 2021.

The population included a substantial proportion of people with type 2 diabetes:

  • 80.5% had type 2 diabetes.
  • 44.9% had obesity.
  • 56.3% were female.
  • The average age was approximately 53 years.

Key findings

Finding 6 months 12 months
Any recorded nutritional deficiency or related complication 12.7% 22.4%
Vitamin D deficiency 7.5% 13.6%
Nutritional anaemia 2.1% 4.0%

The study also reported that approximately 3% of participants had a recorded diagnosis of muscle loss within one year.

Interpreting the one-in-five finding correctly

The reported 22.4% figure is important, but it needs qualification.

This was an observational insurance-claims analysis. The researchers identified recorded diagnoses of deficiencies and related complications. They did not perform systematic biochemical testing on every participant to establish the true prevalence of laboratory-confirmed deficiencies.

Therefore, the finding should be interpreted as approximately one in five patients having a recorded nutritional deficiency or related complication within 12 months, rather than proof that GLP-1 medications caused new deficiencies in one in five users.

The dietitian paradox

Interestingly, participants who had a dietitian visit were more likely to have recorded nutritional deficiencies.

This should not be interpreted as evidence that dietitian care increases nutritional problems.

Patients referred to dietitians may already have higher nutritional risk, more symptoms or greater healthcare engagement. They may also undergo more extensive screening, resulting in more diagnoses being recorded.

This illustrates why observational findings must be interpreted carefully rather than confused with causal evidence.

3.2 Which nutrients deserve attention?

Patients taking GLP-1 medications should pay attention to the nutritional quality of their diets, particularly when appetite suppression substantially reduces food intake.

Potential nutritional concerns include:

  • Protein: inadequate intake may contribute to loss of lean body mass and impair muscle maintenance.
  • Vitamin D: deficiency is common in the general population and was the most frequently recorded deficiency in the 2025 claims study.
  • Vitamin B12: consider particularly in people with diabetes, long-term metformin exposure, restrictive diets or symptoms suggestive of deficiency.
  • Iron: inadequate intake or existing iron deficiency may contribute to anaemia and fatigue.
  • Folate and thiamine: assess when dietary intake is inadequate, particularly with prolonged vomiting or other significant nutritional risk.
  • Calcium and magnesium: consider overall dietary intake and individual clinical risk.

These are potential areas for assessment, not a recommendation that every patient should automatically take all these supplements.

3.3 A practical nutritional monitoring approach

A sensible approach includes:

  1. Assess dietary intake and nutritional status before or early in treatment.
  2. Review changes in appetite, food tolerance and gastrointestinal symptoms.
  3. Monitor protein intake and dietary variety.
  4. Consider laboratory testing according to medical history, symptoms, dietary restrictions and weight-loss trajectory.
  5. Use targeted supplementation when a deficiency or clear nutritional requirement is identified.
  6. Consider registered dietitian support, particularly when food intake is severely restricted or nutritional risks are elevated.

The American Diabetes Association's 2026 Standards of Care also emphasise adequate nutritional intake, personalised nutrition advice, protein adequacy and muscle-strengthening activities during treatment with obesity medications.

People experiencing substantial weight loss, including more than 20% of body weight, or rapid weight loss exceeding 4% per month, warrant particular attention to micronutrient screening.

There is no single universally appropriate laboratory panel or testing schedule for every GLP-1 user. Assessment should be guided by clinical judgment.

4. GLP-1 Medications and Muscle Loss: Protecting the Quality of Weight Loss

Successful obesity treatment should not be judged solely by how much weight someone loses.

The composition of that weight loss is equally important.

Weight reduction involves changes in both fat mass and lean body mass. Although most weight lost with GLP-1-based medications is fat, a clinically relevant proportion can come from lean tissue.

4.1 What does the research show?

A 2026 systematic review and meta-analysis by Eisa and Barood examined 20 randomised controlled trials involving 15,782 participants.

The researchers evaluated changes in lean mass during incretin-based pharmacotherapy and lifestyle interventions.

The percentage of total weight lost attributed to lean mass was estimated as follows:

Treatment Lean mass share of total weight loss
Semaglutide 35.2%
Tirzepatide 25.4%
Liraglutide 26.8%
Lifestyle intervention 26.2%
Lifestyle plus resistance training 17.5%

These findings suggest that lean mass reduction is not unique to GLP-1 medications. It is also a recognised component of substantial weight loss through conventional lifestyle interventions.

However, resistance training appears to improve the proportion of weight lost as lean mass.

Important distinction: Lean mass measurements include more than skeletal muscle. They can include water and other non-fat tissues. A reduction in lean mass does not automatically mean that an equivalent amount of functional muscle has been lost.

4.2 Strategies to preserve muscle

Prioritise adequate protein.

Protein intake should be individually tailored according to body composition, age, activity level, kidney function and overall nutritional needs. Some clinical nutrition frameworks use approximately 1.2–1.6 g/kg/day for suitable adults, but this should not be treated as a universal prescription or calculated indiscriminately using actual body weight.

People with chronic kidney disease or other conditions affecting protein requirements may need different targets.

Incorporate resistance training.

Resistance exercise is particularly important during substantial weight reduction. Exercises using resistance bands, free weights, machines or body weight can help preserve muscle strength and physical function.

A progressive programme performed at least twice weekly may be suitable for many adults, with modifications according to fitness, age and medical limitations.

Monitor functional outcomes.

Weight alone is insufficient. Depending on clinical circumstances, monitoring may include waist circumference, body composition, muscle strength, exercise performance and functional capacity.

Maintain adequate nutritional intake.

Excessive calorie restriction, prolonged meal skipping and inadequate dietary variety can undermine nutritional health during pharmacological weight reduction.

The objective is not simply to become lighter. It is to achieve a healthier body composition while retaining strength and function.

Related reading: How to Prevent Muscle Loss on GLP-1 Medications.

5. Long-Term GLP-1 Treatment: Continue, Reduce or Stop?

Once patients reach their target weight, they may naturally wonder whether they still need medication.

There is no universal answer. The decision depends on treatment response, metabolic benefits, adverse effects, medical history, cost, access and individual preferences.

However, the evidence increasingly supports continued treatment for many people because obesity is often a chronic condition and biological drivers of weight regain can persist.

5.1 Continuing the existing maintenance dose

For patients who have achieved satisfactory weight loss, have good tolerability and continue to experience health benefits, maintaining the current effective dose may be reasonable.

The objective is not necessarily to keep losing weight indefinitely. It is to maintain the benefits achieved.

Importantly, the 2026 Standards of Care in Overweight and Obesity recommend continuing effective obesity medication after treatment goals have been reached because discontinuation often results in weight recurrence and deterioration of cardiometabolic health.

The maintenance dose should balance efficacy, health benefits and tolerability. It does not necessarily have to be the maximum approved dose.

5.2 Reducing to a lower maintenance dose: SURMOUNT-MAINTAIN

One of the most important 2026 developments is the publication of SURMOUNT-MAINTAIN in The Lancet.

This phase 3b randomised controlled trial investigated whether patients who had initially achieved weight loss with tirzepatide could maintain their results by continuing their maximum tolerated dose, reducing to 5 mg or switching to placebo.

Study design

  • Initial treatment: 60 weeks of tirzepatide at the maximum tolerated dose of 10 mg or 15 mg weekly.
  • Participants were subsequently randomised into three groups.
  • Group 1 continued the maximum tolerated dose.
  • Group 2 reduced treatment to 5 mg weekly.
  • Group 3 switched to placebo.
  • The maintenance phase lasted another 52 weeks.

Results at week 112

  • Maximum tolerated dose: 21.9% mean weight reduction from the original baseline.
  • Reduced 5 mg dose: 16.6% mean weight reduction.
  • Placebo: 9.9% mean weight reduction.

Both continued treatment groups maintained significantly more weight loss than the placebo group.

The findings suggest that reducing tirzepatide to 5 mg may be a useful maintenance option for some patients who have previously received higher doses.

However, the lower dose did not maintain the same average weight reduction as continuing the maximum tolerated dose.

This trial supports individualised treatment rather than an assumption that every patient needs the highest dose indefinitely.

Important limitations: The trial was funded by Eli Lilly, and several authors were company employees. Its results also apply to the specific trial population and treatment protocol. Longer follow-up and additional independent research will help establish how broadly these results can be applied.

Reference: Horn DB et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN). The Lancet. 2026;407:2305–2318. DOI: 10.1016/S0140-6736(26)00656-2.

5.3 What does three-year treatment evidence show?

The extended SURMOUNT-1 study provides another perspective on long-term treatment.

In participants with obesity and prediabetes, tirzepatide treatment continued for 176 weeks, approximately three years.

At the 15 mg dose, mean weight reduction was 19.7%, compared with 1.3% in the placebo group.

The incidence of type 2 diabetes was also substantially lower in the tirzepatide groups than in the placebo group: 1.3% versus 13.3% during the treatment period.

These results demonstrate sustained weight reduction and delayed progression to diabetes in the studied population.

They should not, however, be generalised to everyone with obesity, particularly those without prediabetes.

6. What Happens When GLP-1 Treatment Is Stopped?

One of the most consistent findings in obesity pharmacotherapy research is that substantial weight regain commonly follows discontinuation of GLP-1 treatment.

This is not necessarily a sign of treatment failure. It reflects, in part, the persistence of biological mechanisms that promote weight regain after significant weight reduction.

6.1 STEP 1: Semaglutide withdrawal

The STEP 1 trial extension followed participants after semaglutide treatment was discontinued.

During the initial 68-week treatment period, participants receiving semaglutide lost approximately 17.3% of their starting body weight.

During the following year after treatment withdrawal, participants regained approximately 11.6 percentage points, equivalent to about two-thirds of their previous weight loss.

Several cardiometabolic improvements also moved back towards baseline.

6.2 STEP 4: Continuing versus stopping semaglutide

The STEP 4 randomised withdrawal trial provided further evidence.

After an initial 20-week semaglutide treatment period, participants were randomised to continue semaglutide or switch to placebo.

During the subsequent 48 weeks:

  • Those switched to placebo regained approximately 6.9% of body weight.
  • Those continuing semaglutide lost a further 7.9%.

The difference highlights the importance of continued pharmacological treatment in maintaining weight reduction.

6.3 SURMOUNT-4: Tirzepatide withdrawal

A similar pattern was observed with tirzepatide.

Following an initial 36-week treatment period, participants were randomised to continue tirzepatide or switch to placebo.

Over the following 52 weeks, those switched to placebo experienced approximately 14% weight regain, while participants continuing tirzepatide experienced additional weight reduction.

These findings reinforce the concept that ongoing treatment can be important for maintaining the benefits of obesity pharmacotherapy.

6.4 Does everyone regain weight?

No. Individual outcomes vary.

Some people may maintain a substantial proportion of their weight loss after discontinuation, particularly when they have established sustainable dietary and physical activity routines.

However, the available randomised withdrawal evidence indicates that weight regain is common, and lifestyle support alone cannot be assumed to reproduce the benefits of continued medication.

7. Emerging Maintenance Strategies: What Is Supported by Evidence?

Patients and clinicians have explored several approaches to reducing medication exposure while maintaining weight-loss benefits.

These strategies should be separated according to their evidence quality.

7.1 Reduced-frequency dosing

Instead of taking a weekly medication every week, some patients have explored extending the interval between injections.

A 2025 report by Wu and colleagues described two real-world cases and used pharmacokinetic-pharmacodynamic modelling to examine less frequent dosing.

More importantly, a 2026 retrospective case series by Wong and colleagues examined 30 adults who had reached a weight plateau on weekly semaglutide or tirzepatide.

Participants transitioned to reduced-frequency dosing, usually every two weeks, and maintained the strategy for an average of approximately 36 weeks.

The authors reported that average body weight decreased further during the reduced-frequency maintenance period, while skeletal muscle mass remained relatively stable.

These findings are interesting, but the study was a small retrospective case series without a randomised control group.

It cannot establish that every patient can safely maintain weight using less frequent injections.

Changing a medicine from its prescribed weekly schedule is an off-label approach and should not be attempted independently.

7.2 Gradual dose tapering

Another strategy involves gradually reducing medication doses before stopping completely.

The concept is to identify a lower dose that may maintain some of the benefits while reducing exposure.

However, there is currently no well-established tapering schedule proven by large randomised trials to prevent weight regain after stopping semaglutide or tirzepatide.

Small observational reports and conference abstracts have generated interest, but they do not establish that tapering is superior to stopping or continuing at a maintenance dose.

7.3 Microdosing

Microdosing generally refers to taking an amount below the established therapeutic dosing regimen.

It does not have a universally accepted clinical definition and is not supported by robust controlled evidence as a long-term maintenance strategy.

Patients should not count injection-pen clicks, dismantle injection devices or attempt to extract partial doses from single-dose pens to create their own dosing schedules.

These methods can result in inaccurate administration, contamination, medication waste and dosing errors.

7.4 Cycling on and off medication

Some patients consider taking planned breaks from treatment and restarting when appetite or weight increases.

Although this may seem attractive, there is insufficient controlled clinical evidence to establish that cycling on and off GLP-1 medication is an effective long-term maintenance strategy.

Interruptions can also create problems when treatment is restarted, particularly gastrointestinal adverse effects if a patient resumes a previously high dose without appropriate reassessment.

7.5 Switching to another obesity medication

Another possibility is switching to a different approved obesity medication rather than stopping all pharmacological treatment.

Some observational programmes have reported maintenance of weight reduction after patients transitioned from GLP-1 therapy to other anti-obesity medications.

However, evidence remains limited, and the suitability of alternative treatments depends on individual medical history, contraindications, adverse effects and treatment objectives.

8. What Does a Responsible GLP-1 Offboarding Plan Look Like?

Stopping treatment should be treated as a planned clinical transition rather than a simple decision to stop injections.

For patients considering discontinuation, the following areas deserve attention.

Before stopping

  • Review the original indication for treatment.
  • Assess current weight, waist circumference and metabolic health.
  • Review diabetes control and any other conditions being treated.
  • Discuss the likelihood of increased appetite and weight regain.
  • Evaluate nutritional adequacy and physical activity.
  • Agree on a follow-up and reassessment plan.

After stopping

  • Monitor body weight and waist circumference.
  • Review changes in hunger, satiety and eating behaviour.
  • Monitor blood glucose in people with diabetes as clinically appropriate.
  • Continue resistance training and regular physical activity.
  • Maintain adequate protein and micronutrient intake.
  • Reassess cardiometabolic risk factors when indicated.
  • Discuss alternative treatment if clinically important weight regain occurs.

People taking GLP-1 medications for type 2 diabetes should have an appropriate alternative glucose-management plan when treatment is discontinued.

Likewise, patients using these medicines for other established medical indications should discuss the implications of stopping with their prescribing clinician.

8.1 Follow-up for at least one year

The National Institute for Health and Care Excellence (NICE), in its 2025 quality standard QS212, highlights the importance of ongoing advice and support after stopping weight-management medicines.

Its recommendations include:

  • Regular monitoring and feedback for at least one year.
  • Practical action plans to address early signs of weight regain.
  • Development of sustainable dietary and physical activity routines.
  • Social and behavioural support.
  • Access to appropriate follow-up services.

The broader message is that stopping a medication does not mean stopping obesity management.

9. An Integrated Long-Term GLP-1 Management Framework

The evidence reviewed above supports a more comprehensive approach than simply increasing or decreasing a medication dose.

Long-term treatment should involve five interconnected areas.

Domain What to assess Clinical objective
Personalised response Weight response, tolerability, metabolic health and relevant clinical factors. Optimise treatment effectiveness.
Nutritional health Protein intake, food variety, micronutrients and gastrointestinal symptoms. Prevent nutritional inadequacy.
Body composition Lean mass, muscle strength and physical function. Preserve muscle and function.
Medication maintenance Dose, efficacy, adverse effects, access and treatment goals. Maintain benefits using an appropriate regimen.
Long-term follow-up Weight trajectory, metabolic markers, appetite and lifestyle. Reduce recurrence and support long-term health.

10. Questions Patients Should Discuss With Their Healthcare Team

1. Am I responding adequately to my current GLP-1 medication?

Weight reduction should be assessed alongside metabolic health, tolerability, treatment duration and other clinical outcomes.

2. Am I eating enough protein and maintaining adequate nutrition?

Appetite suppression should not result in persistent undernutrition or an unnecessarily restrictive diet.

3. Am I losing muscle as well as fat?

Consider resistance training, strength assessment and, where appropriate, body-composition monitoring.

4. Is my current dose still appropriate?

Maximum dosing is not necessarily the only long-term option. Maintenance dosing should balance benefits and tolerability.

5. What would happen if I stopped treatment?

Discuss the likely return of appetite, potential weight regain and implications for diabetes or other medical conditions.

6. Do I need a structured maintenance or offboarding plan?

Plan follow-up before changing treatment rather than responding only after significant weight regain occurs.

Conclusion: GLP-1 Treatment Is About More Than Weight Loss

The next phase of GLP-1-based obesity treatment is likely to focus increasingly on individualised, sustainable and long-term care.

Genetic research is beginning to explain why treatment responses differ. Nutritional studies highlight the importance of protecting dietary adequacy. Body-composition research reinforces the need to preserve muscle and physical function. Meanwhile, withdrawal studies and the new SURMOUNT-MAINTAIN trial demonstrate why maintenance decisions deserve careful consideration.

There is no single strategy that works for everyone.

Some patients may benefit from continued treatment at their existing dose. Others may achieve satisfactory maintenance with an adjusted dose. Some may need to change medications or discontinue treatment because of adverse effects, contraindications or personal circumstances.

The important distinction is between stopping medication and ending treatment altogether.

Long-term obesity management should remain active even when medication changes.

The ultimate goal is not simply to lose weight. It is to maintain the health benefits of weight reduction, preserve muscle and nutritional health, improve metabolic function and establish a sustainable long-term treatment strategy.


Scientific References and Further Reading

  1. Su QJ et al. Genetic predictors of GLP1 receptor agonist weight loss and side effects. Nature. 2026;653:770–775. DOI: 10.1038/s41586-026-10330-z.
  2. Butsch WS et al. Nutritional deficiencies and muscle loss in adults with type 2 diabetes using GLP-1 receptor agonists: A retrospective observational study. Obesity Pillars. 2025;15:100186. DOI: 10.1016/j.obpill.2025.100186.
  3. Eisa N, Barood O. Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Diabetes, Obesity and Metabolism. 2026;28(6):4818–4827. DOI: 10.1111/dom.70666.
  4. American Diabetes Association. Pharmacologic Treatment of Obesity in Adults: Standards of Care in Overweight and Obesity. Diabetes Care, 2026.
  5. Horn DB et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN). The Lancet. 2026;407:2305–2318. DOI: 10.1016/S0140-6736(26)00656-2.
  6. Jastreboff AM et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. New England Journal of Medicine. DOI: 10.1056/NEJMoa2410819.
  7. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022. DOI: 10.1111/dom.14725.
  8. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021. DOI: 10.1001/jama.2021.3224.
  9. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024. DOI: 10.1001/jama.2023.24945.
  10. Wong M et al. Reduced-Frequency GLP1 Therapy Maintains Weight, Body Composition, and Metabolic Syndrome Improvements: A Case Series. Obesity. 2026. DOI: 10.1002/oby.70137.
  11. Wu CC et al. Less frequent dosing of GLP-1 receptor agonists as a viable weight maintenance strategy. Obesity. 2025;33(7):1232–1236. DOI: 10.1002/oby.24302.
  12. National Institute for Health and Care Excellence. Quality Statement 7: Advice and support after stopping medicines for weight management or completing behavioural interventions. QS212. 2025. NICE guidance.

Medical disclaimer: This article is intended for educational and informational purposes only. It is not a substitute for individual medical assessment, diagnosis or treatment. Do not change, reduce, space or discontinue prescribed medication without discussing your circumstances with a qualified healthcare professional. Nutritional requirements and monitoring should be individualised, particularly for people with diabetes, kidney disease or other medical conditions.

Comments

Popular posts from this blog

GLP-1 Hub 2026: Approved Drugs, Pills vs Injections, Retatrutide & Safety

GLP-1 Cost and Coverage 2026: Self-Pay, Insurance and Pill Prices

NAC vs NAD vs NR vs NMN vs Niacin: What Are the Differences?

GLP-1 for Knee Osteoarthritis: Pain Relief, Weight Loss, PRP, Stem Cells or Surgery?

GLP-1 & AI Research Monitor 2026–2027

GLP-1 Clinical Trials & Research Tracker 2026

Natural GLP-1 Boosters vs Real GLP-1 Drugs: Berberine, Akkermansia and Fibre Compared

How to Prevent Muscle Loss on GLP-1 Drugs: Protein, Resistance Training & Body Composition Guide (2026)

GLP-1 Manual 2026: The Complete Guide to GLP-1 Drugs, Benefits, Risks, Dosing, Muscle Loss & Long-Term Strategy

Top Peptide Protocols 2026: Best Stacks for Fat Loss, Recovery, Anti-Aging & Longevity